#gastroagi — Public Fediverse posts

APASL 2026 Day 1 — What’s shaping hepatology right now?

From HEV insights to HBV biomarkers and AI-driven fibrosis prediction — key discussions are already setting the tone for clinical practice.

We’ve curated the most relevant highlights so you don’t miss what truly matters.

👉 Explore full updates on GastroAGI

#GastroAGI #APASL2026 #Hepatology #LiverDisease #HBV #HEV #MASLD #HCC #MedicalEducation #GIUpdates #MedEd #ClinicalInsights

Recurrent dysphagia after esophageal SEMS?
👉 Don’t assume tumor progression.

📸 X-ray: Stent migrated into stomach

💡 Most common cause: stent migration

🔧 Next step:
✔ Endoscopy
✔ Retrieval ± re-stenting (better fixation)

🎯 Restore swallowing, improve QOL

#EsophagealCancer #GI #Endoscopy #Oncology #Dysphagia #GastroAGI

Recurrent dysphagia after esophageal SEMS?
👉 Don’t assume tumor progression.

📸 X-ray: Stent migrated into stomach

💡 Most common cause: stent migration

🔧 Next step:
✔ Endoscopy
✔ Retrieval ± re-stenting (better fixation)

🎯 Restore swallowing, improve QOL

#EsophagealCancer #GI #Endoscopy #Oncology #Dysphagia #GastroAGI

Recurrent dysphagia after esophageal SEMS?
👉 Don’t assume tumor progression.

📸 X-ray: Stent migrated into stomach

💡 Most common cause: stent migration

🔧 Next step:
✔ Endoscopy
✔ Retrieval ± re-stenting (better fixation)

🎯 Restore swallowing, improve QOL

#EsophagealCancer #GI #Endoscopy #Oncology #Dysphagia #GastroAGI

Recurrent dysphagia after esophageal SEMS?
👉 Don’t assume tumor progression.

📸 X-ray: Stent migrated into stomach

💡 Most common cause: stent migration

🔧 Next step:
✔ Endoscopy
✔ Retrieval ± re-stenting (better fixation)

🎯 Restore swallowing, improve QOL

#EsophagealCancer #GI #Endoscopy #Oncology #Dysphagia #GastroAGI

GLP-1 vs bariatric endoscopy — no clear winner.

Meta-analysis (Obesity Surgery, Apr 2026): similar short-term weight loss, BMI reduction, and glycemic control.
Difference lies in safety:
GLP-1 → GI side effects
Endoscopy → procedural/device risks

Treatment should be individualized. Long-term data needed.

#GastroAGI #Obesity #GLP1 #BariatricEndoscopy #Type2Diabetes

Diffuse continuous colonic wall thickening with pancolitis pattern strongly suggests ulcerative colitis, especially when disease is continuous without skip lesions.

#GastroAGI #UlcerativeColitis #IBD #Gastroenterology #Radiology #CTScan #InflammatoryBowelDisease #GIeducation

🔬 Biopsy smart, not routine.

Knowing when to biopsy—and when not to— can change diagnosis, management, and outcomes in upper GI endoscopy.

From Barrett’s protocols to linitis plastica sampling—precision matters.

#GastroAGI #Endoscopy #UpperGI #Biopsy #Gastroenterology #GIEndoscopy #MedicalEducation

🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?

⚠️ Promising data, but guidelines still need phase III confirmation

#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd

🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?

⚠️ Promising data, but guidelines still need phase III confirmation

#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd

🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?

⚠️ Promising data, but guidelines still need phase III confirmation

#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd

🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?

⚠️ Promising data, but guidelines still need phase III confirmation

#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd

CT chest shows a markedly dilated, fluid-filled oesophagus with smooth distal tapering and no obstructing mass—imaging features suggestive of achalasia.

Diagnosis confirmed on high-resolution manometry (Type II).

Patient underwent POEM, with dysphagia score improving
from 3 → 1.

📌 A nice example of radiology–manometry–endoscopy concordance and clinical response.

#Achalasia #POEM #Gastroenterology #Manometry #GastroAGI

CT chest shows a markedly dilated, fluid-filled oesophagus with smooth distal tapering and no obstructing mass—imaging features suggestive of achalasia.

Diagnosis confirmed on high-resolution manometry (Type II).

Patient underwent POEM, with dysphagia score improving
from 3 → 1.

📌 A nice example of radiology–manometry–endoscopy concordance and clinical response.

#Achalasia #POEM #Gastroenterology #Manometry #GastroAGI

Nutrition is central in cirrhosis care. Malnutrition, sarcopenia, and frailty worsen transplant outcomes.

Early assessment, adequate calories, and high-quality protein prehabilitation preserve muscle and resilience. The waitlist is a window to intervene.

#Cirrhosis #Hepatology #TransplantMedicine #NutritionInCirrhosis #Sarcopenia #MedicalEducation #EvidenceBasedMedicine #GastroAGI

GastroAGI is an AI-powered knowledge platform for gastroenterology & hepatology—built for clinicians, trainees, and researchers.

Evidence-first answers from journals, guidelines, and conferences. No noise. No hallucinations. Just clarity.

#GastroAGI #Gastroenterology #Hepatology #MedicalAI #EvidenceBasedMedicine #MedEd #ClinicalPractice #GIResearch

miR147 protects gut mucosa by strengthening epithelial integrity and controlling inflammation.

Knockout → severe colitis, barrier loss, ↑ permeability.

miR147 targets Ndufa4 to maintain metabolic balance + type I IFN signaling.

Therapeutic potential in IBD & colorectal cancer.

#GastroAGI #IBD #MicroRNA #GutHealth

COBALT Trial (PBC): Despite early termination, adjusted analyses + real-world external controls showed obeticholic acid (OCA) reduces major liver events.

EC (External Control) analysis: 60% risk reduction in the risk of adverse clinical outcomes like death, liver transplantation, or hepatic decompensation.(HR 0.39).

Well-tolerated; pruritus most common.

Highlights power of hybrid RCT + real-world evidence.

#PBC #Hepatology #GastroAGI

A new SVM-based machine-learning model accurately predicts postoperative recurrence in ESCC.

Using factors like age, ECOG, NLR, CPR, CY211, TNM stage & complications, the SVM6+8 model reached 94% sensitivity.

A nomogram predicts 1-, 3-, 5-yr DFS, helping identify high- vs low-risk patients.

Enables personalized follow-up & adjuvant therapy.

#ESCC #AI #Oncology #GastroAGI

Exercise boosts anticancer immunity through the gut microbiome.
(Gastroenterology, Feb 2026)

In resistant tumor models, exercise reshaped microbial metabolism to increase formate, a postbiotic that enhanced CD8 T-cell cytotoxicity via Nrf2 activation, improving antitumor immunity and immunotherapy response.

#GastroAGI #GIOncology #CancerImmunotherapy #GutMicrobiome #ASCO #Gastroenterology

#liverTransplant #cirrhosis #gastroagi

#gastroenterology #gastroagi

#AGA #gastroagi #gastroenterology #liver

📘 Chicago Classification v4.0 updates HRM interpretation with stricter criteria & mandatory clinical correlation.

🔄 Supine + upright swallows required.

🚫 EGJOO now needs ↑IRP in both positions + abnormal confirmatory test.

⚡ Achalasia (Types I–III) must include symptoms & supportive tests (TBE/EndoFLIP).

🔥 DES & Jackhammer diagnosed only when manometry + symptoms align.

#GastroAGI #AGA #ChicagoClassification #Esophagus #Motility #HRM

⚠ Ultra-processed foods (UPFs) & Early Death

A global study shows a 2.7% rise in mortality for every 10% increase in UPF intake.

🍔 Countries with highest UPF intake (US/UK >50%) see up to 14% premature deaths linked to UPFs.

📉 Experts call for taxes, better labeling & healthier food access.

#GastroAGI #Nutrition #PublicHealth #UPF #Diet #Metabolism

⚠ Ultra-processed foods (UPFs) & Early Death

A global study shows a 2.7% rise in mortality for every 10% increase in UPF intake.

🍔 Countries with highest UPF intake (US/UK >50%) see up to 14% premature deaths linked to UPFs.

📉 Experts call for taxes, better labeling & healthier food access.

#GastroAGI #Nutrition #PublicHealth #UPF #Diet #Metabolism

⚠ Ultra-processed foods (UPFs) & Early Death

A global study shows a 2.7% rise in mortality for every 10% increase in UPF intake.

🍔 Countries with highest UPF intake (US/UK >50%) see up to 14% premature deaths linked to UPFs.

📉 Experts call for taxes, better labeling & healthier food access.

#GastroAGI #Nutrition #PublicHealth #UPF #Diet #Metabolism

⚠ Ultra-processed foods (UPFs) & Early Death

A global study shows a 2.7% rise in mortality for every 10% increase in UPF intake.

🍔 Countries with highest UPF intake (US/UK >50%) see up to 14% premature deaths linked to UPFs.

📉 Experts call for taxes, better labeling & healthier food access.

#GastroAGI #Nutrition #PublicHealth #UPF #Diet #Metabolism

⚠ Ultra-processed foods (UPFs) & Early Death

A global study shows a 2.7% rise in mortality for every 10% increase in UPF intake.

🍔 Countries with highest UPF intake (US/UK >50%) see up to 14% premature deaths linked to UPFs.

📉 Experts call for taxes, better labeling & healthier food access.

#GastroAGI #Nutrition #PublicHealth #UPF #Diet #Metabolism

🔪 Two-Stage Hepatectomy (TSH)
A key option for initially irresectable colorectal liver metastases.

🩺 Stage-1: Debulk tumors + allow liver regeneration.

🩸 Stage-2: Remove remaining disease after FLR hypertrophy.

✅ Feasible in ~80%, offering long-term survival & potential cure.

#GastroAGI #CRC #LiverSurgery #Hepatobiliary #Oncology

🔪 Two-Stage Hepatectomy (TSH)
A key option for initially irresectable colorectal liver metastases.

🩺 Stage-1: Debulk tumors + allow liver regeneration.

🩸 Stage-2: Remove remaining disease after FLR hypertrophy.

✅ Feasible in ~80%, offering long-term survival & potential cure.

#GastroAGI #CRC #LiverSurgery #Hepatobiliary #Oncology

🔪 Two-Stage Hepatectomy (TSH)
A key option for initially irresectable colorectal liver metastases.

🩺 Stage-1: Debulk tumors + allow liver regeneration.

🩸 Stage-2: Remove remaining disease after FLR hypertrophy.

✅ Feasible in ~80%, offering long-term survival & potential cure.

#GastroAGI #CRC #LiverSurgery #Hepatobiliary #Oncology

🔪 Two-Stage Hepatectomy (TSH)
A key option for initially irresectable colorectal liver metastases.

🩺 Stage-1: Debulk tumors + allow liver regeneration.

🩸 Stage-2: Remove remaining disease after FLR hypertrophy.

✅ Feasible in ~80%, offering long-term survival & potential cure.

#GastroAGI #CRC #LiverSurgery #Hepatobiliary #Oncology

🧪 Autoantibodies & MASLD Outcomes
ANA (17%) and ASMA (25%) are common in MASLD.
Their presence signals worse prognosis:

⚠️ ~4× higher risk of liver decompensation

⚠️ >2× higher mortality
Autoantibodies act as markers of immune activation and predict
progression to cACLD.

➡️ Useful for risk stratification & closer monitoring.

#GastroAGI #MASLD #Liver

📏 FLIP Panometry Update – Dallas Consensus

🔬 Experts standardized 40 guidelines for performing & interpreting FLIP to reduce variability.

✅ A normal FLIP reliably rules out major motor disorders.

⚠️ ↓EGJ opening + weak contractions = EGJ outflow obstruction.

A major step toward uniform global practice.

#GastroAGI

🔥 HbA1c & Infected Pancreatic Necrosis (IPN)

⚠️ HbA1c ≥6.5% = 4× higher IPN risk in acute necrotizing pancreatitis.

🩸 Hyperglycemia drives immune dysfunction, bacterial translocation & severe inflammation.

📌 Early HbA1c testing + strict glucose control is essential.

#Pancreatitis #IPN #HbA1c #CriticalCare #GastroAGI

🔆 Radiotherapy in HCC: Y90 vs SBRT

• Y90: Injected microspheres → heterogeneous dose, 2–3 mm penetration, radiation over days (t½ ~64h).

• SBRT: External beam → uniform, precise high dose in minutes.

• Y90’s slow delivery ↓ biological effect per Gy; ~400 Gy Y90 ≈ 40–50 Gy SBRT.

#GastroAGI #HCC #Radiotherapy

🧬 Chronic Pancreatitis & Pancreatic Cancer Risk

Meta-analysis shows chronic pancreatitis increases pancreatic cancer risk ~8-fold (HR 7.82), higher than acute pancreatitis (HR 3.54).

Risk is greatest for PDAC (HR 6.57) and IPMN (HR 17.19).

Chronic pancreatitis patients should be considered high-risk, highlighting the need for targeted screening strategies.

#GastroAGI #Pancreas #PancreaticCancer

🫀 Liver Transplantation for CRLM (Colorectal Cancer Liver Metastasis) Multicenter study (n=82) shows strong survival after LT: 1-, 3-, 5-yr OS = 94%, 73%, 55%.

⚠ Women had 4× higher mortality, driven by right-sided tumors, KRAS mutations & higher liver recurrence.

🔍 Poor prognostic factors: CEA >80, large nodules, pN2 nodes.

➡ Calls for sex-aware selection models in LT for CRLM.

#GastroAGI #LiverTransplant #CRLM

🌬️ Breath Biopsy in Cirrhosis
A non-invasive test analyzing VOCs (Volatile Organic Compounds) in exhaled breath.

🔍 7 key VOCs (incl. limonene, 2-pentanone, indole) detected cirrhosis with AUC 0.95.

🧪 Reflects impaired CYP metabolism, detox pathways & gut-liver axis.

📊 VOC patterns also correlate with Child-Pugh severity.

➡️ A promising tool for early detection & staging.

#GastroAGI #Liver #Cirrhosis

⚡🧠 Translumbosacral Neuromodulation Therapy (TNT) – ACG 2025

✨ Major Findings:

🔽 Weekly FI episodes: 7.7 → 2.8

🔽 And 8.3 → 3.5 (dose-dependent)

⚡ Improved pudendal nerve function → suggests neural pathway regeneration

🧪 Status: Promising but still investigational

#GastroAGI #ACG2025 #FecalIncontinence

🧬 Why Immunotherapy Fails in CRC

♟️CRC uses TGF-β to block T-cell entry into tumors

♟️ Inside the tumor, macrophages release osteopontin, weakening T-cells

♟️ Result: “immune-cold” tumors resistant to PD-1/PD-L1 blockers

🔄 Solutions: TGF-β inhibitors, osteopontin blockers + checkpoint therapy show promise in preclinical studies.

#GastroAGI #CRC #Immunotherapy

⚠️ Anastomotic Leak After ESCC Esophagectomy

• Incidence: 21.5%

• High-risk factors: older age, cervical anastomosis, low RBC count, high NLR >14.6, poor nutrition

• Nomogram predictive model: AUC 0.870

• Early CT/POD7 imaging + marker monitoring essential

• Close monitoring & nutritional optimization improve outcomes

#GastroAGI #ESCC #Surgery

🚭 Smoking increases MASLD risk

by 30–41% in a dose-dependent manner; ≥20 pack-years raises risk by ~32%. Passive smoke exposure increases risk by 13%. Mechanisms include oxidative stress, insulin resistance, inflammation, and gut–liver axis disruption.

Quitting smoking for >10 years reduces MASLD risk to levels comparable with non-smokers.

#GastroAGI #MASLD #LiverHealth

🦠 Blown-Out Myotomy (BOM) in Achalasia

BOM occurs when a prior myotomy fails, causing recurrent dysphagia, chest pain, and poor esophageal emptying.

A new study shows POEM is a safe, effective salvage option with 85.7% success at 2 yrs, even in altered anatomy—restoring swallowing and quality of life.
#GastroAGI #Achalasia #POEM

Genetic Testing in Familial Gastric Cancer Genetic testing + H. pylori evaluation helps refine risk in those with a family history of gastric cancer.

Key genes: CDH1, CTNNA1, BRCA1/2, PALB2, MLH1, MSH2.

Early-onset (<40 yrs) & syndromic cases (HDGC, Lynch) warrant testing.

#GastroAGI #GastricCancer #Genetics

Genetic Testing in Familial Gastric Cancer Genetic testing + H. pylori evaluation helps refine risk in those with a family history of gastric cancer.

Key genes: CDH1, CTNNA1, BRCA1/2, PALB2, MLH1, MSH2.

Early-onset (<40 yrs) & syndromic cases (HDGC, Lynch) warrant testing.

#GastroAGI #GastricCancer #Genetics

Genetic Testing in Familial Gastric Cancer Genetic testing + H. pylori evaluation helps refine risk in those with a family history of gastric cancer.

Key genes: CDH1, CTNNA1, BRCA1/2, PALB2, MLH1, MSH2.

Early-onset (<40 yrs) & syndromic cases (HDGC, Lynch) warrant testing.

#GastroAGI #GastricCancer #Genetics

💊 Enfortumab Vedotin (EV) — a Nectin-4–targeted antibody-drug conjugate delivering MMAE to kill tumor cells.
Trial EV-202:

🔹 GEA (Gastroesophageal Adenocarcinoma): ORR 9.5%, limited benefit
🔹 ESCC (Esophageal Squamous Cell Carcinoma): ORR 18.2%, meaningful activity

⚕️ Manageable safety; rash & hyperglycemia common
➡️ Conclusion: EV shows promise as salvage therapy in ESCC, but limited value in GEA. Further combo studies warranted.

#GastroAGI #Oncology #EsophagealCancer

💊 Enfortumab Vedotin (EV) — a Nectin-4–targeted antibody-drug conjugate delivering MMAE to kill tumor cells.
Trial EV-202:

🔹 GEA (Gastroesophageal Adenocarcinoma): ORR 9.5%, limited benefit
🔹 ESCC (Esophageal Squamous Cell Carcinoma): ORR 18.2%, meaningful activity

⚕️ Manageable safety; rash & hyperglycemia common
➡️ Conclusion: EV shows promise as salvage therapy in ESCC, but limited value in GEA. Further combo studies warranted.

#GastroAGI #Oncology #EsophagealCancer

💊 Enfortumab Vedotin (EV) — a Nectin-4–targeted antibody-drug conjugate delivering MMAE to kill tumor cells.
Trial EV-202:

🔹 GEA (Gastroesophageal Adenocarcinoma): ORR 9.5%, limited benefit
🔹 ESCC (Esophageal Squamous Cell Carcinoma): ORR 18.2%, meaningful activity

⚕️ Manageable safety; rash & hyperglycemia common
➡️ Conclusion: EV shows promise as salvage therapy in ESCC, but limited value in GEA. Further combo studies warranted.

#GastroAGI #Oncology #EsophagealCancer

🧬 Pembrolizumab in MSS–TMB-High mCRC
Real-world Japan's Genomic C-CAT data (n=127) show poor outcomes in MSS–TMB-H (Tumor Mutational Burden-High )vs MSI-H–TMB-H-mCRC.

🕒 OS: 4.5 vs 33.6 mo | TTF: 2.0 vs 10.6 mo
Pembrolizumab underperformed vs FTD/TPI (5.4 vs 13.8 mo).

✅ High TMB alone ≠ predictor of benefit.

✅Only rare POLE-mutated MSS tumors responded well.

✅Guideline: avoid ICI use in MSS–TMB-H outside POLE subset.

#GastroAGI #mCRC #Immunotherapy #Oncology

🧬 Pembrolizumab in MSS–TMB-High mCRC
Real-world Japan's Genomic C-CAT data (n=127) show poor outcomes in MSS–TMB-H (Tumor Mutational Burden-High )vs MSI-H–TMB-H-mCRC.

🕒 OS: 4.5 vs 33.6 mo | TTF: 2.0 vs 10.6 mo
Pembrolizumab underperformed vs FTD/TPI (5.4 vs 13.8 mo).

✅ High TMB alone ≠ predictor of benefit.

✅Only rare POLE-mutated MSS tumors responded well.

✅Guideline: avoid ICI use in MSS–TMB-H outside POLE subset.

#GastroAGI #mCRC #Immunotherapy #Oncology

🧬 Pembrolizumab in MSS–TMB-High mCRC
Real-world Japan's Genomic C-CAT data (n=127) show poor outcomes in MSS–TMB-H (Tumor Mutational Burden-High )vs MSI-H–TMB-H-mCRC.

🕒 OS: 4.5 vs 33.6 mo | TTF: 2.0 vs 10.6 mo
Pembrolizumab underperformed vs FTD/TPI (5.4 vs 13.8 mo).

✅ High TMB alone ≠ predictor of benefit.

✅Only rare POLE-mutated MSS tumors responded well.

✅Guideline: avoid ICI use in MSS–TMB-H outside POLE subset.

#GastroAGI #mCRC #Immunotherapy #Oncology

💊 LEAP-014 Trial (AASLD 2025)
Adding lenvatinib to pembrolizumab + chemo failed to improve survival in metastatic esophageal CC.

🕒 OS: 17.6 vs 15.5 mo (HR 0.92; P = .185)

🧪 PFS: 7.2 vs 6.9 mo

⚠️ Similar toxicity, no biomarker advantage.

🔚 Experts: No role for lenvatinib in ESCC.

#GastroAGI #Oncology #EsophagealCancer

💊 LEAP-014 Trial (AASLD 2025)
Adding lenvatinib to pembrolizumab + chemo failed to improve survival in metastatic esophageal CC.

🕒 OS: 17.6 vs 15.5 mo (HR 0.92; P = .185)

🧪 PFS: 7.2 vs 6.9 mo

⚠️ Similar toxicity, no biomarker advantage.

🔚 Experts: No role for lenvatinib in ESCC.

#GastroAGI #Oncology #EsophagealCancer

💊 LEAP-014 Trial (AASLD 2025)
Adding lenvatinib to pembrolizumab + chemo failed to improve survival in metastatic esophageal CC.

🕒 OS: 17.6 vs 15.5 mo (HR 0.92; P = .185)

🧪 PFS: 7.2 vs 6.9 mo

⚠️ Similar toxicity, no biomarker advantage.

🔚 Experts: No role for lenvatinib in ESCC.

#GastroAGI #Oncology #EsophagealCancer